FDA clears IND for phase II trial of CT-868 in overweight and obese patients with type 2 diabetes May 4, 2021
Lysogene initiates phase I/II study of LYS-GM101 gene therapy in infantile GM1 gangliosidosis May 4, 2021
Vivet opens enrollment in phase I/II study of VTX-801 gene therapy for Wilson's disease April 26, 2021
Neurodevelopmental and biomarker data for RGX-121 in a phase I/II study for severe MPS II April 26, 2021
RSS